Compare · DXCM vs KTWO
DXCM vs KTWO
Side-by-side comparison of DexCom Inc. (DXCM) and K2 Capital Acquisition Corporation (KTWO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both DXCM and KTWO operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- DXCM is the larger of the two at $30.44B, about 149.9x KTWO ($203.0M).
- DXCM has been more active in the news (13 items in the past 4 weeks vs 3 for KTWO).
- DXCM has more recent analyst coverage (25 ratings vs 0 for KTWO).
- Company
- DexCom Inc.
- K2 Capital Acquisition Corporation
- Price
- -
- -
- Market cap
- $30.44B
- $203.0M
- 1M return
- -3.21%
- -
- 1Y return
- +42.43%
- -
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2005
- 2026
- News (4w)
- 13
- 3
- Recent ratings
- 25
- 0
DexCom Inc.
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM system for diabetes management; Dexcom G7, a next generation G7 CGM system; and Dexcom Share, a remote monitoring system. DexCom, Inc. has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop next-generation CGM products. The company markets its products directly to endocrinologists, physicians, and diabetes educators. DexCom, Inc. was founded in 1999 and is headquartered in San Diego, California.
Latest DXCM
- EVP Chief Legal Compliance Off Brown Michael Jon covered exercise/tax liability with 1,451 shares, decreasing direct ownership by 1% to 96,734 units (SEC Form 4) to cover withholding tax
- EVP, COO & CFO Sylvain Jereme M covered exercise/tax liability with 1,451 shares, decreasing direct ownership by 0.99% to 145,377 units (SEC Form 4) (for tax liability)
- EVP Chief People & Culture Off Stern Sadie covered exercise/tax liability with 1,451 shares, decreasing direct ownership by 1% to 119,462 units (SEC Form 4) to satisfy withholding obligation
- President, CEO, and Director Leach Jacob Steven covered exercise/tax liability with 1,451 shares, decreasing direct ownership by 0.35% to 417,457 units (SEC Form 4) to satisfy withholding tax
- Dexcom Announces Upcoming Conference Presentation
- SEC Form SCHEDULE 13G filed by DexCom Inc.
- Director Ashley Euan A. gifted 2,389 shares (SEC Form 4)
- Dexcom Invites the Global Diabetes Community to Share Their Stories Through A Letter to Diabetes Campaign
- SEC Form 10-Q filed by DexCom Inc.
- SEC Form 8-K filed by DexCom Inc.
Latest KTWO
- Amendment: SEC Form SCHEDULE 13G/A filed by K2 Capital Acquisition Corporation
- SEC Form 10-Q filed by K2 Capital Acquisition Corporation
- SEC Form SCHEDULE 13G filed by K2 Capital Acquisition Corporation
- K2 Capital Acquisition Corporation filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits
- SEC Form 10-Q filed by K2 Capital Acquisition Corporation
- Providence™ Medical Technology Appoints Lane Major as President & Chief Executive Officer
- SEC Form SCHEDULE 13G filed by K2 Capital Acquisition Corporation
- Amendment: SEC Form SCHEDULE 13G/A filed by K2 Capital Acquisition Corporation
- SEC Form 10-Q filed by K2 Capital Acquisition Corporation
- SEC Form SCHEDULE 13G filed by K2 Capital Acquisition Corporation